Insider Trading activities at Aardvark Therapeutics, Inc. (AARD)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aardvark Therapeutics, Inc. (AARD) since 2025 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aardvark Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1774857.

Total stock buying since 2025: $23,160,000.
Total stock sales since 2025: $0.
Total stock option exercises since 2025: $72,966.


4 insiders reported insider trading activities at Aardvark Therapeutics, Inc. (AARD):
Insider trading activities of Cui Xiangmin
Insider trading activities of Chen Bihua
Insider trading activities of Lee Tien-li
Insider trading activities of Sun Nelson

Table 1. Yearly summary of insider stock purchases, sales, and option exercises at Aardvark Therapeutics, Inc. (AARD).
Insider Buying Insider Sales Option Exercises
Year Shares Value Shares Value Shares Value
2025 1,447,500 $23,160,000 0 $0 17,209 $72,966

Table 2. Monthly summary of insider trading at Aardvark Therapeutics, Inc. (AARD).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2025-08 0 $0 0 $0 17,209 $72,966
2025-02 1,447,500 $23,160,000 0 $0 0 $0

Table 3. Detailed insider trading at Aardvark Therapeutics, Inc. (AARD)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2025-08-28 Lee Tien-li (Chief Executive Officer) Option Ex 17,209 4.24 72,966
2025-02-14 Sun Nelson (Chief Financial Officer) Buy 10,000 16.00 160,000
2025-02-14 Chen Bihua Buy 187,500 16.00 3,000,000
2025-02-14 Cui Xiangmin Buy 1,250,000 16.00 20,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of AARD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aardvark Therapeutics, Inc. (symbol AARD, CIK number 1774857) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.